RxDoctor Payments Data

Marco Davila, MD

Medical Oncology · Buffalo, NYNPI 1326204322

Payments from drug & device makers

$799,847in general payments, 2019–2025

Across 327 payments — averaging $2446.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$374K
  • E.r. Squibb & Sons, L.L.C.$221K
  • Gilead$175K
  • Bristol Myers Squibb$9K
  • Incyte Corporation$7K
  • Legend Biotech USA Inc.$6K
  • plus $8K from 5 others

What the payments were for

  • Consulting fees$54,33512%
  • Speaking & faculty fees$322,74374%
  • Travel & lodging$49,00411%
  • Food & beverage$11,1063%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis41$374,144
E.r. Squibb & Sons, L.L.C.138$220,904
Gilead(2 entities)112$174,779
Bristol Myers Squibb12$9,158
Incyte Corporation9$7,056
Legend Biotech USA Inc.9$6,257
GSK1$5,937
Johnson & Johnson2$925
ADIR1$550
ADC Therapeutics America, Inc.1$100
Sobi, Inc1$37

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$799,847 in reported general payments places this provider in the 65th percentile of 498 medical oncology providers in New York.

See all medical oncology providers in New York

Medicare billing

Part B allowed, 2024
$7,957
Medicare patients
29
Services billed
82

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other medical oncology in Buffalo

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →